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Background: Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and
subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces
symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently,
ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for
treatment of allergic rhinitis with and without conjunctivitis.
Methods: This was an analysis of pooled data for a prespecified subgroup of Canadian subjects from two multicentre,
randomized, double-blind placebo-controlled trials of ragweed sublingual tablet (SLIT-T; 6 and 12 Amb a 1-U of
Ambrosia artemisiifolia) in patients aged ≥18y, with ragweed-induced allergic rhinoconjunctivitis (AR/C) with or
without asthma. Randomized subjects used once-daily ragweed SLIT-T or placebo for at least 12 weeks before the
ragweed season and for up to 52 weeks post-randomization. The primary efficacy endpoint was the total combined
score (TCS) based on the sum of AR/C daily symptom score (DSS) and daily medication score (DMS) averaged over the
peak season. Treatment effects on TCS, DSS, and DMS in the entire season were also assessed. Adverse events (AEs)
were monitored to assess safety.
Results: 337 Canadian subjects were randomized in the two trials. During the peak season, ragweed SLIT-T 6 and 12
Amb a 1-U significantly reduced TCS by 26% (difference, −2.46 score point; p = .0009) and 40% (difference, −3.75 score
point; p < .0001), respectively. In the overall population (N = 961), TCS reductions with 6 and 12 Amb a 1-U were 20%
and 23%, respectively (both p < .001). Clinically meaningful reductions in entire-season TCS in Canadians were similar to
those during peak ragweed season. Dose-dependent reduction of DSS and DMS was also observed for ragweed SLIT-T
6 and 12 Amb a 1-U during the peak season and the entire season. Ragweed SLIT-T was well tolerated in Canadian
subjects and the overall population. Adverse events were generally mild to moderate and transient, occurring early in
treatment; no systemic allergic reaction/anaphylaxis was noted.
Conclusion: Ragweed SLIT-T is an effective form of immunotherapy that provides symptomatic efficacy of AR/C with a
favorable risk profile in Canadian and overall populations.
Trial registration: Clinicaltrials.gov identifiers NCT00783198 and NCT00770315.
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Short or “common” ragweed (Ambrosia artemisiifolia)
pollen is among the more common causes of respiratory
allergies in North America [1]. Ragweed allergy is a
longstanding treatment challenge in eastern Canada
[2,3], and the recent lengthening of ragweed pollen season,
which is especially pronounced in higher latitudes of
North America, has contributed to the problem [4]. Rag-
weed is common in the provinces of Quebec and Ontario,
while it is rare in British Columbia [5]. Results of allergy
testing of 2595 individuals in regions across Canada found
the overall prevalence of allergen sensitization was 62.7%,
and up to 33% of subjects were positive to ragweed [6].
Allergic rhinitis with or without conjunctivitis (AR/C)
is typically induced by animal dander, dust mites, moulds
and pollens. The first line of treatment is avoidance, but
allergen avoidance is difficult with pollens, necessitating
the use of pharmacotherapy [7]. Treatment of ragweed
allergy with subcutaneous injections has also been
shown to be effective [8-10]. Unlike pharmacotherapy,
immunotherapy targets the immunologic cause of re-
spiratory symptoms and is the only treatment that alters
the course of respiratory allergic disease [7]. However,
the inconvenience of injections may make some patients
reluctant to undergo this form of treatment. Studies
have found that factors related to both inconvenience
and safety contribute to premature discontinuation of
subcutaneous immunotherapy [11,12].
The treatment of ragweed allergy with ragweed sub-
lingual immunotherapy tablet (SLIT-T) MK-3641 (12
Amb a 1-U of Ambrosia artemisiifolia; Merck & Co, Inc.,
Whitehouse Station, NJ, USA/ALK-Abelló, Hørsholm,
Denmark) has been approved as a new treatment option
for patients with AR/C. Two large North American trials
found MK-3641 6 and 12 Amb a 1-U to be effective and
well tolerated for ragweed-pollen–induced AR/C [13,14].
These two trials involved Canadian subpopulations, and it
was of interest to examine the effects of ragweed SLIT-T
in Canadian subjects in view of the significant morbidity
caused by ragweed in that population [15].
Methods
Study design
An analysis of pooled data for the pre-specified subgroup
of Canadian subjects from two multicentre, randomized,
double-blind placebo-controlled trials of MK-3641 6 and
12 Amb a 1-U in patients with ragweed-induced AR/C
with or without asthma was conducted. One trial (protocol
P05233; clinicaltrials.gov identifier NCT00783198) included
13 centres in Canada, and the other trial (protocol P05234;
clinicaltrials.gov identifier NCT00770315) included 12
centres in Canada. Both trial protocols were approved by
local or centre-specific ethic review boards (P05233, IRB
Services; P05234, BMC REB Montreal Chest Institute ofthe MUHC, Hamilton Health Sciences/Faculty of Health
Sciences Research Ethics Board, and IRB Services), and all
patients gave written informed consent. Trial P05234
included subjects randomized to a dose of MK-3641 (1.5
Amb a 1-U) that was found clinically ineffective and was
excluded from the pooled analysis. Trial P05233 did
not assess a dose of 1.5 Amb a 1-U. Both trials were
conducted over the 2010 ragweed season and had the same
study design; the methodologies have been published
elsewhere [13,14].
The primary hypothesis in both trials was that ragweed
SLIT-T is superior to placebo as measured by improve-
ment in total combined score (TCS) averaged during the
peak ragweed pollen season (RS). The peak RS was
defined as the 15 consecutive recorded days within RS
with the highest 15-day moving average pollen count for
each site. The RS was defined as the period from the
first day of three consecutive recorded days with a pollen
count of ≥10 grains/m3 to the last day of the last occur-
rence of three consecutive recorded days with a pollen
count ≥10 grains/m3, inclusively [13].
Randomized subjects were treated once daily with either
MK-3641 or placebo for at least 12 weeks before the RS,
during the entire RS, and after the end of RS for up to
52 weeks post-randomization. MK-3641 dissolves within
seconds of application, does not require up-titration, and
was administered at the office for the first three doses and
then self-administered at home for the remainder of
the trial. As an added safety measure, all subjects were
supplied with self-injectable epinephrine and instructions
on how and when to use it. Open-label rescue medications
for AR/C were provided. Key inclusion and exclusion
criteria are listed below.
Key eligibility criteria
Inclusion criteria
 Patients had to have been willing to give informed
written consent and be able to adhere to dose and
visit schedules
 18 to 50 years of age, of either sex and of any race
 Clinical history of significant ragweed-induced
AR/C of two years’ duration or more with or
without asthma (diagnosed by a physician) and
have received treatment for the disease during the
previous RS
 Positive skin prick test response to Ambrosia
artemisiifolia (wheal size ≥5 mm larger than saline
control) at the screening visit
 Positive for specific IgE against Ambrosia
artemisiifolia (≥IgE Class 2 [≥0.70 kU/L]) at the
screening visit.
 Forced expiratory volume in 1 second of at least
70% of predicted value at the screening visit
Kim et al. Allergy, Asthma & Clinical Immunology 2014, 10:55 Page 3 of 9
http://www.aacijournal.com/content/10/1/55 Safety laboratory tests and vital signs conducted at
the screening visit must be within normal limits or
clinically acceptable to the investigator/sponsor
Exclusion criteria
 Clinical history of symptomatic seasonal allergic
rhinitis and/or asthma having received regular
medication, owing to another allergen during or
potentially overlapping the RS
 Clinical history of significant symptomatic perennial
allergic rhinitis and/or asthma having received
regular medication due to another allergens to
which the subject is regularly exposed
 Received an immunosuppressive treatment within
three months prior to the screening visit (except
steroids for allergic and asthma symptoms)
 Clinical history of severe asthma
 History of asthma requiring medium- or high-dose
inhaled corticosteroids
 History of anaphylaxis with cardiorespiratory
symptoms
 History of chronic urticaria and angioedema
 Clinical history of chronic sinusitis during the two
years prior to the screening visit
 Current severe atopic dermatitis
 Female subject who was breastfeeding, pregnant, or
intending to become pregnant
 Previous immunotherapy treatment with ragweed
allergen or any other allergen within the five years
prior to the screening visit
 History of allergy, hypersensitivity or intolerance to
the ingredients of the medicinal products (except for
Ambrosia artemisiifolia), rescue medications, or
self-injectable epinephrine
 History of self-injectable epinephrine use
AR/C, allergic rhinitis with or without conjunctivitis;
IgE, immunoglobulin E; RS, ragweed pollen season.
Efficacy assessment
The primary efficacy endpoint was the TCS based on the
combined (sum of) AR/C daily symptom score (DSS) and
daily medication score (DMS) averaged over the peak RS.
Symptoms and medication use were recorded in an elec-
tronic diary once daily in the evening before bed. A total
of six AR/C symptoms (runny nose, blocked nose, sneez-
ing, itchy nose, gritty eyes, and watery eyes) were scored
on a scale of 0 (none) to 3 (severe), for a maximum total
daily symptom score of 18 [13]. Daily rescue medication
use for AR/C was transformed to a DMS by applying
score/dose units for desloratadine, olopatadine ophthalmic
solution, mometasone furoate nasal spray, and prednisone
tablets (Table 1) [13]. Secondary endpoints included TCSover the entire season as well as the individual DSS and
DMS averaged over the peak and entire season.
Safety assessment
Adverse events (AEs), vital signs, physical examinations,
and safety laboratory assessments were summarized by
overall treatment groups.
Statistical analysis
Analyses were performed based on pooled data across two
studies for the entire population as well as the Canadian
subpopulation. The efficacy endpoints were analyzed
using analysis of variance model adjusted for factors
such as treatment, pollen region, and asthma status.
The least squares mean and two-sided 95% CI for the
between-treatment differences were estimated from the
models for the entire population, with the associated
p values reported.
Multiplicity control on testing multiple endpoints was
applied by using a stepwise method for the entire
population analyses, and nominal p values without any
adjustment for multiplicity were reported for the Canadian
subgroup analyses. The percentage reduction relative to
placebo effect was calculated as (MK-3641–placebo)/
placebo × 100% using the within-group least squares
means for the MK-3641 group and the placebo group.
Patients who took at least one dose of study medica-
tion and who had at least one post-randomization diary
record were included in the efficacy analysis [13].
Results
Baseline demographics
Demographics for the entire population of the two trials
have been published previously [13,14], but are included
here because results for Canada are presented in the
context of results for the entire tested population. The
Canadian subpopulation receiving MK-3641 6 Amb a 1-U,
MK-3641 12 Amb a 1-U, or placebo included 337 subjects
in the two pooled trials. The treatment groups had similar
characteristics at randomization; 89–95% of patients were
also sensitized to multiple nonragweed allergens including
other pollen and perennial allergens, and 22–27% of
patients reported concomitant intermittent-to-mild stable
asthma with predicted FEV1 > 70% (Table 2). Across all
treatment groups in the entire randomized population,
80–82% of patients were polysensitized and 18–21% of
patients had concurrent asthma. At randomization,
Canadian subjects had mean specific immunoglobulin E
(sIgE) against A. artemisiifolia at serum levels ranging from
17.8–20.4 kU/L across the treatment groups (Table 2).
In contrast, the entire population had mean sIgE (A.
artemisiifolia) serum levels ranging from 14–18 kU/L
across the treatment groups [13,14].
Table 1 Scoring of rescue medication use [13]
Rescue medication Score/dose unit Maximum daily score
Desloratadine (10 mg/tablet) – 1 tablet QD 6/tablet 6
Olopatadine hydrochloride 0.1% ophthalmic solution (one drop in the affected eye BID) 1.5/drop 6
Mometasone furoate nasal spray 50 μg QD (2 sprays in each nostril) 2/spray 8
Prednisone tablet 5 mg (Day 1: 1 mg/kg/d; max 50 mg/d;
days 2+: 0.5 mg/kg/d; max 25 mg/d)
1.6/tablet 16
TOTAL 36
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The average ragweed season in Canada lasted approxi-
mately 31 days and was characterized by mean peak
pollen counts of 103 grains/m3 in trial P05233 and 95
grains/m3 in trial P05234. In the entire population, the
average ragweed season lasted approximately 45 days
and was characterized by mean peak pollen counts of
122 grains/m3 in trial P05233 and 127 grains/m3 in trial
P05234.
Efficacy results
The overall treatment effect of MK-3641 was dose
dependent. Compared with placebo during the peak
season, MK-3641 6 and 12 Amb a 1-U significantly reduced
TCS among Canadian subjects by 26% (difference, −2.46
score point; p = .0009) and 40% (difference, −3.75 score
point; p < .0001), respectively, in the pooled data for the
two trials, and these results were generally consistent
with those seen in the overall North American studyTable 2 Demographics and baseline characteristics in the Can
Characteristic 6 Amb
MK-3641
Female, n (%) 51 (4
Age, mean (range), y 36.2 (18.0
Race, n (%)
White 84 (7
Black or African American 7(6.
American Indian or Alaskan native 2 (1
Asian 17 (1
Multiracial 2 (1
History of asthma, n (%) 22 (1
Tobacco use, n (%) 31 (2
Duration of ragweed allergy, mean, y 18.
Skin prick test, mean (SD) wheal measurement, mm
Histamine positive control n = 111
Saline negative control n = 111
Ambrosia artemisiifolia extract n = 111
Serum sIgE (Ambrosia artemisiifolia), mean (SD) kU/L n = 112
Polysensitized, n (%) 95 (8
Amb a 1-U, Ambrosia artemisiifolia units; sIgE, specific immunoglobulin E.population (Figure 1). Mean TCS differences from placebo
during the peak season ranged from −1.70 to −3.75
overall, with a trend toward slightly greater reductions
in the Canadian subgroup than in the entire population
(Figure 2). During the entire season, the pooled data
revealed that MK-3641 6 and 12 Amb a 1-U signifi-
cantly reduced TCS among Canadian subjects by 22%
(difference, −1.75 score point; p = .0036) and 37% (dif-
ference, −2.91 score point; p < .0001), respectively,
compared with placebo (Table 3).
In the Canadian subgroup, dose-dependent reductions
of mean DSS and DMS were also observed for MK-3641
6 and 12 Amb a 1-U during the peak ragweed season as
well as the entire season. Reductions of peak-season
scores, when symptoms and medication use are at their
highest levels, were generally greater than reductions
during the entire season (Table 3). Overall, during the
peak and entire ragweed seasons, reduction of DSS was
statistically significant for MK-3641 12 Amb a 1-U vsadian subgroup pooled for two studies
a 1-U
(n =112)




5.5) 59 (53.6) 49 (42.6)
–50.0) 35.8 (19.0–51.0) 36.9 (18.0–51.0)
5.0) 93 (84.5) 86 (74.8)
3) 6 (5.5) 7 (6.1)
.8) 0 0
5.2) 9 (8.2) 20 (17.4)
.8) 2 (1.8) 2 (1.7)
9.6) 23 (20.9) 27 (23.5)
7.7) 24 (21.8) 33 (28.7)
5 17.4 17.4
5.7 (1.66) n = 108 5.7 (1.45) n = 114 5.6 (1.60)
0.7 (1.20) n = 108 0.6 (1.04) n = 114 0.5 (0.99)
12.2 (4.48) n = 110 12.1 (3.96) n = 115 11.8 (4.03)
17. 8 (19.8) n = 110 19.4 (23.4) n = 115 20.4 (23.2)
4.8) 89 (80.9) 90 (78.3)
Figure 1 Pooled results for mean TCS during the peak ragweed pollen season in the Canadian subgroup and the entire population in
two trials.
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vs placebo (p ≥ .0677). During the peak season, DSS
reductions of 14% and 25%, respectively, occurred with
MK-3641 6 and 12 Amb a 1-U compared with placebo.
Reductions in DSS of 11% and 23%, respectively, occurred
with MK-3641 6 and 12 Amb a 1-U during the entire
season. During the peak season, DMS reductions of 45%Figure 2 Differences between mean effects of MK-3641 and placebo
subgroup and the entire population in two trials.and 63%, respectively, occurred with MK-3641 6 and 12
Amb a 1-U compared with placebo. Reductions in DMS
of 44% and 64%, respectively, occurred with MK-3641 6
and 12 Amb a 1-U during the entire season. During the
peak and entire seasons, DMS reductions were statisti-
cally significant for both doses of MK-3641 vs placebo
(p < .0001).on TCS during peak ragweed pollen season in the Canadian
Table 3 Mean TCS, DSS, and DMS during the peak season and the entire season in the Canadian subgroup
Peak season Entire season
6 Amb a 1-U
MK-3641 (n = 87)
12 Amb a 1-U
MK-3641 (n = 94)
Placebo
(n = 104)
6 Amb a 1-U
MK-3641 (n = 88)
12 Amb a 1-U
MK-3641 (n = 94)
Placebo
(n = 104)
TCS 7.03 5.74 9.49 6.06 4.91 7.82
Difference vs placebo (95% CI) −2.46 (−3.90, −1.02) −3.75 (−5.16, −2.34) −1.75 (−2.93, −0.58) −2.91 (−4.07, −1.75)
p value .0009 < .0001 .0036 < .0001
Reduction vs placebo 25.95% 39.52% 22.44% 37.23%
DSS 5.09 4.44 5.95 4.51 3.91 5.05
Difference vs placebo (95% CI) −.86 (−1.78, .06) −1.52 (−2.42, −.61) −.54 (−1.33, .24) −1.14 (−1.92, −.37)
p value .0677 .0011 .1746 .0038
Reduction vs placebo 14.46% 25.49% 10.72% 22.66%
DMS 1.93 1.30 3.53 1.55 1.00 2.77
Difference vs placebo (95% CI) −1.60 (−2.36, −.84) −2.23 (−2.97, −1.49) −1.21 (−1.81, −.61) −1.77 (−2.35, −1.18)
p value < .0001 < .0001 < .0001 < .0001
Reduction vs placebo 45.29% 63.14% 43.82% 63.84%
Amb a 1-U, Ambrosia artemisiifolia units.
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MK-3641 was well tolerated in the Canadian subgroup
as well as the entire study population. Adverse events
were generally assessed as mild or moderate and transient,
and they generally occurred early in treatment. No deaths,
treatment-related systemic allergic reactions, or serious
treatment-related serious AEs occurred. Local reactions of
the mouth, throat, and ear were the most common
treatment-related AEs (TRAEs) (Table 4) [13,14]. In theTable 4 Summary of overall adverse events in the entire pop
Entire population Entire population
6 Amb a 1-U
MK-3641 (n =385)
12 Amb a 1-U
MK-3641 (n =381)
AE Category, n (%)
Any TEAEs 296 (76.9) 307 (80.6)
Any TRAEs 213 (55.3) 233 (61.2)
Any serious TEAEs 5 (1.3) 3 (0.8)
Any serious TRAEs 0 0
Any TEAEs leading to
study discontinuation
31 (8.1) 35 (9.2)
Any TRAEs leading to
study discontinuation
26 (6.8) 31 (8.1)
TRAEs in ≥5% of subjects, n (%)
Oral pruritus 83 (21.6) 66 (17.3)
Ear pruritus 54 (14.0) 54 (14.2)
Throat irritation 90 (23.4) 96 (25.2)
Mouth edema 38 (9.9) 37 (9.7)
Eye pruritus 16 (4.2) 15 (3.9)
Nasal passage irritation 14 (3.6) 15 (3.9)
Skin pruritus 24 (6.2) 10 (2.6)
AE, adverse event; PBO, placebo; TEAE, treatment-emergent adverse event; TRAE, trCanadian subpopulation, 34%, 75%, and 81% of subjects in
the placebo, 6 Amb a 1-U, and 12 Amb a 1-U groups, re-
spectively, experienced a TRAE. In the entire population,
25%, 55%, and 61% of subjects in the placebo, 6 Amb a
1-U, and 12 Amb a 1-U groups, respectively, experi-
enced a TRAE. Overall, there was a non-significant
trend toward more AEs and a higher discontinuation
rate due to AEs in the Canadians compared to the entire




6 Amb a 1-U
MK-3641 (n =112)




264 (68.4) 100 (89.3) 104 (94.5) 93 (80.9)
98 (25.4) 84 (75.0) 89 (80.9) 39 (33.9)
4 (1.0) 1 (0.9) 0 1 (0.9)
0 0 0 0
9 (2.3) 16 (14.3) 15 (13.6) 2 (1.7)
6 (1.6) 14 (12.5) 14 (12.7) 1 (0.9)
10 (2.6) 40 (35.7) 36 (32.7) 7 (6.1)
6 (1.6) 24 (21.4) 30 (27.3) 2 (1.7)
21 (5.4) 39 (34.8) 43 (39.1) 9 (7.8)
2 (0.5) 20 (17.9) 17 (15.5) 2 (1.7)
5 (1.3) 9 (8.0) 5 (4.5) 1 (0.9)
14 (3.6) 7 (6.3) 5 (4.5) 2 (1.7)
6 (1.6) 12 (10.7) 3 (2.7) 2 (1.7)
eatment-related adverse event.
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gency department in response to mild pharyngeal edema
and other local allergic events. The subject had experienced
local events during prior administrations of the tablet. The
investigator considered the AE probably treatment-related,
although the differential diagnosis on admission to the
emergency department was allergic reaction versus anxiety.
The subject recovered from the event and discontinued
MK-3641.
Discussion
In the two efficacy trials evaluating MK-3641, a significant
reduction in symptoms and medication usage versus
placebo among the Canadian subjects with ragweed-
pollen–induced AR/C was demonstrated. These trials
illustrated a dose–response effect of once-daily MK-3641,
with 12 Amb a 1-U showing the greatest reductions in the
primary endpoint of TCS during the peak RS. Treatment
with 12 Amb a 1-U ragweed allergy immunotherapy tablet
provided significant clinical benefit to AR/C subjects, as
shown by improvement in the TCS, DSS, and DMS during
the peak RS, when subjects were suffering the most due to
the highest exposure to ragweed pollen. In addition to
providing clinical effects during the height of the pollen
season, similar findings occurred during the entire rag-
weed pollen season. Furthermore, results in Canadian
subjects were similar to results observed in the entire
North American study population.
Overall safety profiles of MK-3641 6 and 12 Amb a 1-U
were similar, with a numerically greater treatment effect
for 12 Amb a 1-U. Hence, the recommended therapeutic
dose is 12 Amb a 1-U. The first three days of treatment
with MK-3641 were administered in the physician’s office,
although trials with sublingual grass immunotherapy
tablet have shown that one day of in-office treatment is
sufficient and three days of in-office treatment does not
provide an additional safety advantage [16]. Treatment
with MK-3641 was well tolerated for up to one year.
The most frequently reported TRAEs occurred early
and were transient, self-limited local reactions of the
mouth, throat, and ears (primarily oral pruritus, throat
irritation, and ear pruritus), and the majority of events
were assessed as mild or moderate in severity. No ser-
ious TRAEs or systemic reactions were reported, and no
upper airway obstruction, death, anaphylactic shock or
life-threatening events occurred. However, there was a
trend toward more adverse events in the Canadian sub-
group, the significance of which is uncertain considering
that the study was not designed or powered for this
assessment. There was also a trend toward greater efficacy
in the Canadian subgroup. These trials assessed one year
of treatment for ragweed AR/C, while immunotherapy
typically is maintained for several years. Also, it has been
suggested that local application site reactions maycompromise blinding of treatments and bias the results
[17]. A predefined exploratory assessment of treatment
with MK-3641 12 Amb a 1-U and placebo in subjects
with or without local reactions suggests unblinding due to
local reactions did not impact the overall efficacy assess-
ment [18].
Guidelines from the World Allergy Organization and
Allergic Rhinitis and its Impact on Asthma emphasize
that high-dose sublingual immunotherapy is effective,
well tolerated, and safe for self-administration [19,20].
Previously, only a limited number of studies have evalu-
ated sublingual treatments for ragweed allergy [21-24].
Two of these trials were conducted in Canada [22,24]. The
trials of MK-3641 differed from the previously published
Canadian ragweed trials in several important ways. First,
MK-3641 is a sublingual immunotherapy tablet, whereas
the other trials evaluated a liquid sublingual swallow extract
[22,24]. MK-3641 was administered to randomized subjects
at a fixed dose of 6 or 12 Amb a 1-U from the beginning to
the end of treatment, without up-titration. By contrast,
the sublingual swallow extracts were administered with an
initial progression of increasing doses, and the highest-
tolerated dose was used for maintenance treatment
[22,24]. One of the sublingual swallow trials evaluated
ragweed extract doses of at least 116 Amb a 1-U, with a
target dose of 348 Amb a 1-U [22]. The other sublingual
swallow trial evaluated extract doses of up to 50 Amb a
1-U [24], whereas the present MK-3641 trials evaluated
maximum doses of 12 Amb a 1-U. Results from one
sublingual swallow extract trial showed no significant
effect on the total rhinitis, conjunctivitis, or medication
scores [22], whereas the other showed significant reduction
of total combined and daily symptoms scores but did not
evaluate medication scores [24]. These trials used higher
doses of Amb a 1-U than were used in the MK-3641 trial.
Conversely, MK-3641 treatment resulted in significant
improvements of daily symptom and medication scores
as well as the total combined score.
Conclusions
MK-3641, a novel therapeutic modality of ragweed SLIT-T,
significantly improved AR/C caused by ragweed pollen
in Canadian adults aged ≥18 years. MK-3641 is an ef-
fective form of immunotherapy that provides symptom-
atic efficacy of AR/C with a favorable risk profile. Local
allergic events are expected with sublingual administration
of allergen. Although these events occur, they are man-
ageable, resolve typically without treatment, and have
not resulted in airway obstruction. No concerning or
new safety signals emerged, and MK-3641 was tolerated
in subjects with intermittent-to-mild stable asthma. In
conclusion, these trials support the use of 12 Amb a 1-U
ragweed SLIT-T for self-administration at home after the
first dose given under medical supervision has been
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apy may prove to be a valuable treatment option for pa-
tients with ragweed allergy, as suggested by international
guidelines.
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